Shilpa is a member of the founding scientific team at Nura Bio and serves as Chief Scientific Officer. She is spearheading Nura Bio’s state-of-the art neurobiology capabilities as well as playing a pivotal role in driving research strategy and preclinical pipeline development. Prior to Nura Bio, Shilpa spent several years at Amgen and NGM Biopharmaceuticals. Most recently, as a Project Team Lead at Amgen, she successfully launched and supported drug discovery programs in the neuroscience therapeutic area with a focus on neurodegenerative diseases. Shilpa received her undergraduate degree in biological sciences from the Birla Institute of Technology and Science in Pilani, India. Her PhD research conducted in the lab of Professor David Eisenberg at the Howard Hughes Medical Institute, UCLA, was focused on defining fundamental structural features of aggregation-prone proteins implicated in neurodegenerative diseases. Shilpa was also a Bio-X Genentech Foundation postdoctoral fellow at Stanford University with Professor Axel Brunger.